Does Testosterone Therapy Affect Pelvic Pain in Transgender Adolescents?

Why It Matters

The findings suggest testosterone may not be the primary driver of pelvic pain in trans‑masculine youth, informing clinicians’ risk‑benefit discussions around gender‑affirming hormone therapy. Accurate data can help reduce unnecessary treatment hesitancy and improve pain‑management strategies for this vulnerable population.

Key Takeaways

• 69% of testosterone‑using adolescents reported pelvic pain vs 90% non‑users
• Over 80% of pain cases pre‑dated hormone initiation
• Orgasm triggered pain in 59% of testosterone group, 24% of non‑users
• Heat therapy relieved discomfort for ~70% of users
• Study limited to 102 Australian patients; results may not generalize

Pulse Analysis

Pelvic pain remains a leading cause of school absenteeism and social withdrawal among adolescents assigned female at birth, and its prevalence spikes in transgender and gender‑diverse youth seeking gender‑affirming care. Historically, clinicians have suspected that testosterone could exacerbate or even trigger new abdominal discomfort by altering pelvic floor musculature or uterine lining activity. However, robust data have been scarce, especially for younger patients, leaving providers to balance hormone benefits against uncertain pain risks.

The recent exploratory survey conducted at the Royal Children’s Hospital Gender Service in Melbourne fills a critical gap. By comparing 102 respondents—about 60% of whom were on long‑acting testosterone injections—the study uncovered a counter‑intuitive pattern: testosterone users reported pelvic pain at a lower rate (69%) than non‑users (90%). Moreover, more than four‑fifths of those experiencing pain indicated it began before hormone therapy, and only 17% attributed onset to testosterone. Notably, orgasm emerged as a pain trigger for 59% of the hormone group versus 24% of peers, hinting at nuanced hormonal‑related sensitivities. Participants favored heat therapy and over‑the‑counter NSAIDs, with roughly two‑thirds finding relief.

While the results are promising, the study’s cross‑sectional design, modest sample size, and single‑clinic recruitment constrain generalizability. Longitudinal research tracking pain trajectories before, during, and after testosterone initiation is essential to disentangle hormonal effects from baseline dysmenorrhea. For clinicians, the current evidence supports a more individualized approach: discussing the likelihood that testosterone may not worsen pelvic pain, while still monitoring for specific triggers such as orgasm. Ultimately, nuanced data empower providers to offer gender‑affirming hormone therapy with greater confidence, reducing unnecessary barriers for trans‑masculine adolescents seeking comprehensive care.